AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Highlights
- First patient has been dosed under the phase 1 clinical trial of onCarlytics CD19 virus technology.
- onCARlytics might offer a solution to treat solid tumours which remain untreated by CD-19 targeting biological drugs, says IMU.
- The dose escalation trial is being conducted at City of Hope, California, and multiple sites across the US.
Imugene Limited (ASX: IMU) has reported the commencement of Phase 1 clinical trial on its CD19 oncolytic virotherapy drug candidate onCARlytics. As part of the trial, the first patient has been dosed at the NCI-Designated Comprehensive Cancer Center of the City of Hope in California, the US.
OASIS, the first-in-class trial of onCARlytics, is being conducted in patients with advanced or metastatic solid tumours.
The title of the study is –
Data source: Company update
The study is a dose escalation trial, which aims at assessing the efficacy and safety of two routes of administration –
- Only intratumoral (IT) injection and intravenous (IV) infusion or
- In combination with blinatumomab.
The company states that onCARlytics has the potential to eradicate and target solid tumours when it is combined with the CD19 targeting bispecific monoclonal antibody blinatumomab (Amgen’s Blincyto®), that otherwise cannot be treated with Blincyto® therapy alone.
Data source: Company update
IMU shares traded at AU$0.042 apiece at the time of writing on 26 October 2023.
